CTLA4 and melanoma: The creation of these blocking antibody therapeutics was not the only development in the field as an outcome of these basic biologic studies; recently CTLA‐4 promoter methylation was shown to be a viable biomarker for the efficacy of immune checkpoint blockade specifically in melanoma and subsequently in renal cell carcinoma (ccRCC).12